The Mitochondrial Gap
The Biological Necessity of UA.01
As early as age 30, the body’s ability to recycle damaged mitochondria, a process called Mitophagy, begins to decelerate. This leads to a buildup of "cellular debris," resulting in reduced ATP (energy) production and the onset of systemic "inflammaging."
The 70% Digestive Lottery
Urolithin A is the world’s most potent mitophagy activator. However, clinical data shows that 70% of humans lack the specific gut microbiome profile required to convert dietary precursors into active Urolithin A.
The 50% Decline
Mitochondrial quality-control capacity can decline by up to 50% across adulthood. This leads to the accumulation of dysfunctional mitochondria that leak oxidative waste and accelerate cellular aging.
The Bioenergetic Deficit
Damaged mitochondria consume more resources while producing significantly less ATP. This metabolic debt results in decreased physical endurance and cognitive fatigue that cannot be solved by stimulants alone.
The 70% Digestive Lottery
Urolithin A is the world’s most potent mitophagy activator. However, clinical data shows that 70% of humans lack the specific gut microbiome profile required to convert dietary precursors into active Urolithin A.
The 50% Decline
Mitochondrial quality-control capacity can decline by up to 50% across adulthood. This leads to the accumulation of dysfunctional mitochondria that leak oxidative waste and accelerate cellular aging.
The Bioenergetic Deficit
Damaged mitochondria consume more resources while producing significantly less ATP. This metabolic debt results in decreased physical endurance and cognitive fatigue that cannot be solved by stimulants alone.
The TriPhase Mito Systemâ„¢ MOA
How UA.01 orchestrates cellular renovation through three distinct biological stages.
Phase 1: Selective Mitophagy (Renew)
The Biological Objective:
Clear the cellular "metabolic debt".
The Mechanism:
Urolithin A triggers the PINK1/Parkin signaling pathway, which identifies dysfunctional mitochondria that have reached a critical state of decay.
The Outcome:
These damaged units are tagged and recycled into raw materials, reducing oxidative waste and systemic "inflammaging".
Proven Impact:
Clinical data demonstrates up to a 104% increase in mitophagy markers within 24 hours of administration.
Phase 2: Mitochondrial Biogenesis (Rebuild)
The Biological Objective:
Expand the cellular energy infrastructure.
The Mechanism:
With the cellular environment cleared, PQQ stimulates PGC-1α, known as the "master regulator" of mitochondrial biogenesis.
The Outcome:
This phase signals your cells to synthesize new, high-density mitochondrial networks to replace the recycled units.
Proven Impact:
PQQ has been demonstrated to be up to 5,000 times more efficient than Vitamin C in recycling redox cofactors during biogenesis.
Phase 3: ATP Production (Refuel)
The Biological Objective:
Maximize sustained energy output.
The Mechanism:
The Electron Transport Chain (ETC) in the newly formed mitochondria is optimized using Ubiquinol (CoQ10).
The Outcome:
By facilitating efficient electron transfer, the system maximizes the production of ATP, the fundamental unit of human energy, while minimizing free radical production.
Proven Impact:
Ubiquinol is essential for 95% of total human cellular energy production.
High-Potency Bio-Actives
We don't "label dress" with trace amounts. UA.01 is formulated with clinically relevant dosages designed to match or exceed the levels used in peer-reviewed human research.
Urolithin A (500mg)
PQQ (20mg)
Coenzyme Q10 (240mg)
The Network Synergy
Evidence-Based Outcomes
Third-Party Validation Every batch of UA.01 undergoes rigorous testing for:
Purity
Verification of active compound concentrations via HPLC.
Safety
Screening for heavy metals (Lead, Mercury, Arsenic) and microbial contaminants.
Integrity
100% Glyphosate-free and Non-GMO.
See Current Certificate of Analysis (COA) PDF
Click Here to See our Most Recent COA
Citations & References
The Evidence Base UA.01 is formulated based on a foundational library of over 500 peer-reviewed studies and clinical trials. Our core efficacy is anchored by the following human clinical endpoints:
- Mitochondrial Health & Mitophagy: Nature Metabolism (2019). "The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial health in humans."
- Muscle Endurance & Strength: JAMA Network Open (2022). "Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health."
- Biogenesis Pathway Activation:Â Journal of Biological Chemistry. "PQQ-induced mitochondrial biogenesis via PGC-1alpha."
- Systemic Energy (ATP) Support:Â Journal of Pharmacy & BioAllied Sciences. "The essential role of Coenzyme Q10 in the Electron Transport Chain."
- Safety & Toxicology:Â Food and Chemical Toxicology. "Safety evaluation of Urolithin A as a novel food ingredient."